Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana, 46285.
J Pharm Sci. 2013 Nov;102(11):3888-99. doi: 10.1002/jps.23717. Epub 2013 Sep 5.
Basic guidance on the photostability testing of pharmaceuticals, designed to cover manufacturing and storage over shelf life, has long been established within ICH Q1(ICH,B(10) , but the guideline does not cover the photostability of drugs during or after administration (i.e., under conditions of use). To date, there has been a paucity of guidance covering the additional testing that would be of value during the clinical preparation and use of products. This commentary suggests a systematic approach, based on realistic "worst case" photoexposure scenarios and the existing ICH Option 1 and 2 light sources, to provide valuable data to pharmaceutical manufacturers and compounding pharmacists for the safe and effective use of photosensitive injection products.
药物光稳定性测试的基本指南早已在 ICH Q1(ICH,B(10))中确立,旨在涵盖制造和储存过程中的保质期,但该指南并未涵盖药物在给药期间或之后的光稳定性(即在使用条件下)。迄今为止,几乎没有涵盖在产品的临床准备和使用过程中进行有价值的额外测试的指导。本评论建议采用基于现实的“最坏情况”光暴露情况和现有的 ICH 选项 1 和 2 光源的系统方法,为制药商和制剂药师提供有价值的数据,以确保光敏注射产品的安全有效使用。